Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK.

Oncogene. 2019 Jul 9. doi: 10.1038/s41388-019-0862-y. [Epub ahead of print]

PMID:
31289363
2.

RE: Straight-to-test faecal tagging CT colonography for exclusion of colon cancer in symptomatic patients under the English 2-week-wait cancer investigation pathway: a service review. A reply.

Stephenson JA, Pancholi J, Ivan CV, Mullineux JH, Patel H, Verma R, Elabassy M.

Clin Radiol. 2019 Aug;74(8):644. doi: 10.1016/j.crad.2019.05.001. Epub 2019 Jun 17. No abstract available.

PMID:
31221470
3.

Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.

Chari NS, Ivan C, Le X, Li J, Mijiti A, Patel AA, Osman AA, Peterson CB, Williams MD, Pickering CR, Caulin C, Myers JN, Calin GA, Lai SY.

J Natl Cancer Inst. 2019 May 24. pii: djz097. doi: 10.1093/jnci/djz097. [Epub ahead of print]

PMID:
31124563
4.

Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling.

Vasyutin I, Zerihun L, Ivan C, Atala A.

Anticancer Res. 2019 Mar;39(3):1105-1118. doi: 10.21873/anticanres.13219.

PMID:
30842139
5.

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M.

Breast Cancer Res. 2019 Feb 1;21(1):20. doi: 10.1186/s13058-019-1104-5.

6.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

7.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.

Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S.

Br J Cancer. 2019 Feb;120(3):340-345. doi: 10.1038/s41416-018-0360-y. Epub 2019 Jan 14.

PMID:
30636774
8.

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25.

9.

EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.

An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N.

Oncogene. 2019 Mar;38(12):2123-2134. doi: 10.1038/s41388-018-0565-9. Epub 2018 Nov 19.

10.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
11.

Diagnosing and Treating Sleep Apnea in Patients With Acute Cerebrovascular Disease.

Bravata DM, Sico J, Vaz Fragoso CA, Miech EJ, Matthias MS, Lampert R, Williams LS, Concato J, Ivan CS, Fleck JD, Tobias L, Austin C, Ferguson J, Radulescu R, Iannone L, Ofner S, Taylor S, Qin L, Won C, Yaggi HK.

J Am Heart Assoc. 2018 Aug 21;7(16):e008841. doi: 10.1161/JAHA.118.008841.

12.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.

PMID:
30305341
13.

Circular RNAs: Methodological challenges and perspectives in cardiovascular diseases.

Carrara M, Fuschi P, Ivan C, Martelli F.

J Cell Mol Med. 2018 Nov;22(11):5176-5187. doi: 10.1111/jcmm.13789. Epub 2018 Sep 11. Review.

14.

OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.

Monroig-Bosque PDC, Shah MY, Fu X, Fuentes-Mattei E, Ling H, Ivan C, Nouraee N, Huang B, Chen L, Pileczki V, Redis RS, Jung EJ, Zhang X, Lehrer M, Nagvekar R, Mafra ACP, Monroig-Bosque MDM, Irimie A, Rivera C, Dan Dumitru C, Berindan-Neagoe I, Nikonowicz EP, Zhang S, Calin GA.

Sci Rep. 2018 Aug 30;8(1):13106. doi: 10.1038/s41598-018-30989-3.

15.

[Bullous pemphigoid localised to a strip of skin].

Ivan C, Kassem Youssef H, Backobi E, Chouta Ngaha F, Nojavan H, Michel C.

Ann Dermatol Venereol. 2018 Oct;145(10):636-637. doi: 10.1016/j.annder.2018.06.004. Epub 2018 Aug 7. French. No abstract available.

PMID:
30097211
16.

Profiling the circulating miRnome reveals a temporal regulation of the bone injury response.

Silva AM, Almeida MI, Teixeira JH, Ivan C, Oliveira J, Vasconcelos D, Neves N, Ribeiro-Machado C, Cunha C, Barbosa MA, Calin GA, Santos SG.

Theranostics. 2018 Jun 24;8(14):3902-3917. doi: 10.7150/thno.24444. eCollection 2018.

17.

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK.

Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y.

18.

Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer.

Eastlack SC, Dong S, Ivan C, Alahari SK.

Mol Cancer. 2018 Jul 16;17(1):100. doi: 10.1186/s12943-018-0851-8.

19.

Straight-to-test faecal tagging CT colonography for exclusion of colon cancer in symptomatic patients under the English 2-week-wait cancer investigation pathway: a service review.

Stephenson JA, Pancholi J, Ivan CV, Mullineux JH, Patel H, Verma R, Elabassy M.

Clin Radiol. 2018 Sep;73(9):836.e1-836.e7. doi: 10.1016/j.crad.2018.05.013. Epub 2018 Jun 30.

PMID:
29970243
20.

Benign Sclerosing and Fibrosing Conditions of the Abdomen and Their Potential Mimics.

Mullineux JH, Ivan CV, Pancholi J, Verma R, Rajesh A, Verma S, Stephenson JA.

J Clin Imaging Sci. 2018 May 31;8:21. doi: 10.4103/jcis.JCIS_19_18. eCollection 2018. Review.

21.

Peripheral vision: abdominal pathology missed outside the centre of gaze.

Ivan CV, Mullineux JH, Shah V, Verma R, Rajesh A, Stephenson JA.

Br J Radiol. 2018 Nov;91(1091):20180142. doi: 10.1259/bjr.20180142. Epub 2018 Jun 27. Review.

PMID:
29927632
22.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122387. doi: 10.1172/jci.insight.122387. eCollection 2018 Jun 7. No abstract available.

23.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. eCollection 2018 Jun 7. No abstract available.

24.

ADH1B promotes mesothelial clearance and ovarian cancer infiltration.

Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK.

Oncotarget. 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344. eCollection 2018 May 18.

25.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

26.

Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.

Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA.

PLoS One. 2018 May 16;13(5):e0195932. doi: 10.1371/journal.pone.0195932. eCollection 2018.

27.

Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.

Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B.

Clin Cancer Res. 2018 Sep 1;24(17):4225-4241. doi: 10.1158/1078-0432.CCR-17-1959. Epub 2018 May 10.

PMID:
29748184
28.

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.

Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z.

Cancer Lett. 2018 Aug 28;430:47-56. doi: 10.1016/j.canlet.2018.05.009. Epub 2018 May 8.

PMID:
29746929
29.

Snack food as a modulator of human resting-state functional connectivity.

Mendez-Torrijos A, Kreitz S, Ivan C, Konerth L, Rösch J, Pischetsrieder M, Moll G, Kratz O, Dörfler A, Horndasch S, Hess A.

CNS Spectr. 2018 Oct;23(5):321-332. doi: 10.1017/S1092852918000767. Epub 2018 Apr 4.

PMID:
29616603
30.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

31.

Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK, Matei D.

Cancer Res. 2018 Jun 1;78(11):2990-3001. doi: 10.1158/0008-5472.CAN-17-2319. Epub 2018 Mar 6.

32.

Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.

Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK.

Front Oncol. 2018 Feb 9;8:9. doi: 10.3389/fonc.2018.00009. eCollection 2018.

33.

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli M.

Nat Commun. 2018 Jan 31;9(1):461. doi: 10.1038/s41467-018-02851-7.

34.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2018 Jan 8;9(1):160. doi: 10.1038/s41467-017-02485-1.

35.

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.

Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G.

Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262. doi: 10.1016/j.omtn.2017.06.023. Epub 2017 Jul 5.

36.

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.

Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK.

Mol Cancer Ther. 2018 Feb;17(2):464-473. doi: 10.1158/1535-7163.MCT-17-0006. Epub 2017 Dec 13.

37.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2017 Nov 27;8(1):1801. doi: 10.1038/s41467-017-01562-9. Erratum in: Nat Commun. 2018 Jan 8;9(1):160.

38.

Standardization of 67Cu and calibration of the ionization chamber. Impurities and decay scheme problems.

Sahagia M, Luca A, Ioan MR, Antohe A, Ivan C.

Appl Radiat Isot. 2018 Apr;134:297-301. doi: 10.1016/j.apradiso.2017.10.036. Epub 2017 Oct 19.

PMID:
29107515
39.

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V.

Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3.

40.

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).

Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK.

Oncogene. 2018 Feb 8;37(6):722-731. doi: 10.1038/onc.2017.348. Epub 2017 Oct 23.

41.

TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p.

Berrout J, Kyriakopoulou E, Moparthi L, Hogea AS, Berrout L, Ivan C, Lorger M, Boyle J, Peers C, Muench S, Gomez JE, Hu X, Hurst C, Hall T, Umamaheswaran S, Wesley L, Gagea M, Shires M, Manfield I, Knowles MA, Davies S, Suhling K, Gonzalez YT, Carragher N, Macleod K, Abbott NJ, Calin GA, Gamper N, Zygmunt PM, Timsah Z.

Nat Commun. 2017 Oct 16;8(1):947. doi: 10.1038/s41467-017-00983-w.

42.

Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.

Le Meur G, Lebranchu P, Billaud F, Adjali O, Schmitt S, Bézieau S, Péréon Y, Valabregue R, Ivan C, Darmon C, Moullier P, Rolling F, Weber M.

Mol Ther. 2018 Jan 3;26(1):256-268. doi: 10.1016/j.ymthe.2017.09.014. Epub 2017 Sep 19.

43.

Reply to Akingboye et al.

Ivan CV, Mullineux JH, Verma R, Shah V, De A, Elabassy M, Rajesh A, Stephenson JA.

Colorectal Dis. 2018 Jan;20(1):76-77. doi: 10.1111/codi.13916. No abstract available.

PMID:
29027365
44.

Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.

Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy ML.

J Neurooncol. 2018 Jan;136(1):33-39. doi: 10.1007/s11060-017-2622-6. Epub 2017 Sep 30.

45.

Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation.

Brady LK, Wang H, Radens CM, Bi Y, Radovich M, Maity A, Ivan C, Ivan M, Barash Y, Koumenis C.

PLoS Biol. 2017 Sep 29;15(9):e2002623. doi: 10.1371/journal.pbio.2002623. eCollection 2017 Sep.

46.

Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.

Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G.

Cell Discov. 2017 Sep 12;3:17029. doi: 10.1038/celldisc.2017.29. eCollection 2017.

47.

Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK.

Nat Commun. 2017 Aug 21;8(1):310. doi: 10.1038/s41467-017-00411-z.

48.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. eCollection 2017 Aug 17.

49.

Assessment of the inferior mesenteric vein diameter as a surrogate marker to evaluate response to neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma.

Ivan CV, Mullineux JH, Verma R, Shah V, De A, Elabassy M, Rajesh A, Stephenson JA.

Colorectal Dis. 2017 Dec;19(12):1076-1080. doi: 10.1111/codi.13811.

PMID:
28696522
50.

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.

Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA.

Genome Biol. 2017 May 24;18(1):98. doi: 10.1186/s13059-017-1224-0.

Supplemental Content

Support Center